Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01484678
Recruitment Status : Recruiting
First Posted : December 2, 2011
Last Update Posted : December 31, 2018
Sponsor:
Collaborators:
University of Pennsylvania
Oregon Health and Science University
Children's Hospital of Philadelphia
Shriners Hospitals for Children
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Information provided by (Responsible Party):
University of Florida

Tracking Information
First Submitted Date October 10, 2011
First Posted Date December 2, 2011
Last Update Posted Date December 31, 2018
Study Start Date May 2010
Estimated Primary Completion Date April 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: April 26, 2016)
  • Change from baseline in intramuscular lipid up to 5-10 years [ Time Frame: Change in baseline up to 5-10 years ]
    MR measures of intramuscular lipid will be measured in yearly intervals for a period up to 5-10 years.
  • Change from baseline in muscle T2 up to 3 months [ Time Frame: Change in baseline up to 3 months ]
    In a subgroup of subjects the effect of corticosteroids on muscle T2 will be measured at 3 and 6 months. Muscle T2 is a noninvasive marker of muscle damage/inflammation and will be measured using MR. This substudy requires its own Primary and Secondary Outcome measures.
Original Primary Outcome Measures
 (submitted: November 30, 2011)
  • Change from baseline in intramuscular lipid at 1 year [ Time Frame: up to 5 years ]
    MR measures of intramuscular lipid will be measured in yearly intervals for a period up to 5 years.
  • Change from baseline in muscle T2 at 3 months [ Time Frame: 3 months ]
    In a subgroup of subjects the effect of corticosteroids on muscle T2 will be measured at 3 and 6 months. Muscle T2 is a noninvasive marker of muscle damage/inflammation and will be measured using MR. This substudy requires its own Primary and Secondary Outcome measures.
Change History Complete list of historical versions of study NCT01484678 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures
 (submitted: April 26, 2016)
  • Change from baseline in muscle T2 up to 5-10 years [ Time Frame: Change in baseline up to 5-10 years ]
    Muscle T2 will be measured in the lower extremity and/or upper extremity muscles using MR at yearly intervals up to 5-10 years. We will report the change for each year interval.
  • Change from baseline in muscle contractile area up to 5-10 years [ Time Frame: change in baseline up to 5-10 years ]
    Muscle contractile area will be measured in the lower extremity and/or upper extremity muscles using MR at yearly intervals up to 5 years. We will report the change for each year interval.
  • Change from baseline in muscle T2 at 6 months [ Time Frame: Change in baseline up to 6 months ]
    In a subgroup of subjects the effect of corticosteroids on muscle T2 will be measured at 3 and 6 months. Muscle T2 is a noninvasive marker of muscle damage/inflammation and will be measured using MR. This substudy requires its own Primary and Secondary Outcome measures.
Original Secondary Outcome Measures
 (submitted: November 30, 2011)
  • Change from baseline in muscle T2 at 1 year [ Time Frame: up to 5 years ]
    Muscle T2 will be measured in the lower extremity muscles using MR at yearly intervals up to 5 years. We will report the change for each year interval.
  • Change from baseline in muscle contractile area at 1 year [ Time Frame: up to 5 years ]
    Muscle contractile area will be measured in the lower extremity muscles using MR at yearly intervals up to 5 years. We will report the change for each year interval.
  • Change from baseline in muscle T2 at 6 months [ Time Frame: 6 months ]
    In a subgroup of subjects the effect of corticosteroids on muscle T2 will be measured at 3 and 6 months. Muscle T2 is a noninvasive marker of muscle damage/inflammation and will be measured using MR. This substudy requires its own Primary and Secondary Outcome measures.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
Official Title Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy; The Relationship Between Genomic Variants And MRI/MRS Markers In DMD
Brief Summary

The purpose of this research study is to determine the potential of magnetic resonance imaging to monitor disease progression and to serve as an objective outcome measure for clinical trials in Duchenne Muscular Dystrophy (DMD). The investigators also hope to learn more about the changes that occur in muscles of the lower leg and arm in boys with DMD.

The investigators will compare the muscles of ambulatory or non-ambulatory boys with DMD with muscles of healthy children of the same age and monitor disease progression in boys with DMD over a 5-10 year period. The amount of muscle damage and fat that the investigators measure will also be related to performance in daily activities, such as walking and the loss of muscle strength. In a small group of subjects the investigators will also assess the effect of corticosteroid drugs on the muscle measurements.

Detailed Description

The overall objective of this proposal is to validate the potential of noninvasive magnetic resonance imaging (MRI) and spectroscopy (MRS) to monitor disease progression and to serve as an outcome measure for clinical trials in Duchenne muscular dystrophy (DMD). DMD is one of the most devastating genetically linked neuromuscular diseases and is characterized by the absence of dystrophin, resulting in progressive muscle weakness, loss of walking ability and premature death. Despite the poor prognosis for patients with muscular dystrophy, therapeutic interventions have been lacking, and outcome measures for clinical trials have been limited to measures of muscle function, serum biomarkers of muscle breakdown and invasive muscle biopsies. Additional quantitative outcome measures that are noninvasive and sensitive to changes in muscle structure and composition are needed to facilitate the rapid translation of promising new interventions from preclinical studies to clinical trials. As such, this proposal targets the development and validation of magnetic resonance as a noninvasive biomarker of disease progression in muscular dystrophy. Using a multi-site research design this study will examine the intramuscular lipid content, muscle damage/inflammation and contractile area in the lower extremity and/or upper extremity muscles of 200 ambulatory or non-ambulatory boys with DMD and 100 healthy age matched boys using a combination of MRI and MRS technologies. In order to assess the sensitivity of each MR measure to disease progression, all boys with DMD will be reevaluated in yearly or 6 month intervals. In addition, the investigators will correlate changes in MR measures with standard measures of disease progression, such as loss in muscle strength and functional ability. Using MRI/MRS the investigators will also examine the effect of initiating corticosteroid treatment on skeletal muscle characteristics and composition. Finally, the investigators will deposit immortalized fibroblasts from carefully characterized DMD boys participating in this study in established tissue repositories.

The investigators anticipate that the MR techniques developed and validated in this proposal will be suitable for clinical trials in a wide range of muscular dystrophies and other neuromuscular diseases. In addition, MR characterization may serve as a powerful tool to further advance our understanding of the pathogenesis of muscular dystrophy and help guide the design of future trials.

Study Type Observational
Study Design Observational Model: Case-Control
Time Perspective: Prospective
Target Follow-Up Duration Not Provided
Biospecimen Retention:   Samples With DNA
Description:
Blood and Skin Samples Collected
Sampling Method Non-Probability Sample
Study Population Subjects will be recruited from across the country as well as locally. The investigators have established a website (www.imagingDMD.org) and advertise the study nationally through list serves.The study will also be advertised at the website of non-profit DMD organizations. General information will be emailed to faculty and colleagues around the country. Fliers and brochures will be distributed in participating local clinics, MDA clinics, schools, and local pediatric clinics, and in strategic locations in associated hospitals. Age-matched healthy boys will be recruited from the families of the local DMD population as well as the university community. Parents of eligible subjects will be asked to contact the site clinical coordinator, who will complete a telephone screening interview to assess eligibility.
Condition Duchenne Muscular Dystrophy
Intervention Not Provided
Study Groups/Cohorts
  • Age Matched Controls
    Age matched non-affected (non-DMD) boys
  • Boys with DMD
    This group will include ambulatory and non-ambulatory boys with Duchenne Muscular Dystrophy ranging form 5-18 years old.
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: January 31, 2018)
200
Original Estimated Enrollment
 (submitted: November 30, 2011)
150
Estimated Study Completion Date April 2020
Estimated Primary Completion Date April 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria for boys with DMD:

  1. Ambulatory and non-ambulatory males (ages 5-18) previously diagnosed with DMD based on:

    • clinical features with onset of symptoms before age five
    • elevated serum creatine kinase level or
    • absence of dystrophin expression, as determined by immunostain or western blot (<2%) and/or DNA confirmation of a dystrophin mutation.
  2. Subjects will not be excluded based on corticosteroid treatment

Inclusion Criteria for age matched controls:

1. Ambulatory males (ages 5-18) without disease or injury to the lower extremities

Exclusion Criteria:

  1. Males with a contraindication to an MR examination
  2. Males with unstable medical problems
  3. Males who are not able to cooperate during testing
  4. Males with a secondary condition that may impact muscle metabolism, muscle function or functional ability (i.e. cerebral palsy, endocrine disorders, mitochondrial disease)
  5. Healthy boys who participate in competitive sports specific training in excess of 8 hours per week. Participation in multiple recreational sports activities is not an exclusion.
Sex/Gender
Sexes Eligible for Study: Male
Ages 5 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers Yes
Contacts
Contact: Krista Vandenborne, PhD 352-273-6100 kvandenb@phhp.ufl.edu
Contact: Claudia Senesac, PhD 352-273-6453 csenesac@phhp.ufl.edu
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01484678
Other Study ID Numbers IRB201700056-N
R01AR056973 ( U.S. NIH Grant/Contract )
176-2010 ( Other Identifier: Univeristy of Florida )
OCR16243 ( Other Identifier: University of Florida )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party University of Florida
Study Sponsor University of Florida
Collaborators
  • University of Pennsylvania
  • Oregon Health and Science University
  • Children's Hospital of Philadelphia
  • Shriners Hospitals for Children
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Investigators
Principal Investigator: Gihan Tennekoon, MD Children's Hospital of Philadelphia
Principal Investigator: William Rooney, PhD Oregan Health and Science University
Principal Investigator: H. Lee Sweeney, PhD University of Florida
Principal Investigator: Krista Vandenborne, PhD University of Florida
PRS Account University of Florida
Verification Date December 2018